Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
04.06. | Arecor Therapeutics - Grant of Options and PDMR Dealing | - | RNS | ||
02.06. | Arecor Therapeutics - Result of AGM | - | RNS | ||
02.06. | Arecor Therapeutics - Non-Executive Director Board Change | - | RNS | ||
ARECOR THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
21.05. | Arecor Therapeutics - Director/PDMR Dealing | 1 | RNS | ||
20.05. | Skye and Arecor to develop higher formulation of CB1 inhibitor | 2 | Pharmaceutical Technology | ||
19.05. | AIM Market Roundup: The Revel Collective, Tanfield, Arecor | 3 | The Armchair Trader | ||
19.05. | Arecor shares climb 18% on collaboration with Skye Bioscience | 4 | Alliance News | ||
19.05. | Arecor enters formulation partnership with Skye Bioscience | 2 | Sharecast | ||
19.05. | Skye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab | 240 | GlobeNewswire (Europe) | SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other... ► Artikel lesen | |
19.05. | Arecor Therapeutics - Arecor Partnership with Skye Bioscience | 2 | RNS | ||
14.05. | Arecor Therapeutics - Director Dealing | - | RNS | ||
08.05. | Arecor Therapeutics - Arecor sells rights to non-Ogluo® products | - | RNS | ||
06.05. | Arecor Therapeutics - Posting of 2024 Annual Report and Notice of AGM | 1 | RNS | ||
24.04. | Arecor Therapeutics - Arecor to present on Investor Meet Company | - | RNS | ||
23.04. | Arecor Therapeutics - Grant of Options and PDMR Dealing | 1 | RNS | ||
22.04. | Arecor Therapeutics sees 'significant future growth' as revenue rises | 1 | Alliance News | ||
22.04. | Arecor Therapeutics - Final results for 2024 | - | RNS | ||
10.04. | Arecor Therapeutics - Notice of Results | - | RNS | ||
26.03. | Arecor Therapeutics - Collaboration with global pharmaceutical partner | - | RNS | ||
12.03. | Arecor Therapeutics strikes deal for development of peptide therapy | 2 | Alliance News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |